CARE™ Needs Assessment Results

Gastroenterologists Managing Patient with IBD

Biosimilars & Access to Innovation

Gastroenterology

30 Jul 2021

Sample of Key Takeaways

The response data provides the average of all responders.

  • More data on biosimilar outcomes in a Canadian practice setting are needed. 3.8/5
  • Health care providers will be required to offer additional patient interaction time to implement non-medical switches. 4.9/5
  • Current polices will allow savings from biosimilar adoption to fund access to new therapies. 2.5/5
Sample of Response Data